Lu Ke

Institution
Chinese Academy of Sciences

Country
China

Field
Materials Sciences

Lu is the winner of the 2020 Future Science Prize (Physical Science Prize) for discovering and synthesizing a superior nanotwinned structure and gradient nanostructure.

(Photo: Future Science Prize)

AWARDS
  • Future Science Prize 2020

Related articles

Moving The Needle In Liquid Biopsy

Twist Bioscience is optimizing cancer research workflows with a new library preparation kit and improved reference standard for next-generation sequencing of cell-free DNA.

Golden Connections

Today’s connectivity technologies are helping older people in Asia stay socially active and take charge of their own wellbeing.
Empty syringes

Turning The Tide On Dengue: How Climate Change, Urbanization And Innovation Shape Control Strategies

Tackling dengue requires a holistic approach—integrating immunization through vaccines and community-driven initiatives can nip dengue in the bud.

NSCC Singapore Launches Latest Supercomputers To Advance Research

Supported by a S$270 million grant from the National Research Foundation, the National Supercomputing Centre Singapore has announced their plans to support Singapore’s research community and develop the nation’s high-performance computing capabilities.

Can Tech Help You Sleep Better?

Asia is going through a sleep crisis, worse than anywhere else in the world, leading to a growth in the market of sleep wearables. But how much do they help?

Accelerating HPC Industry Innovation

High Performance Supercomputing is supercharging industry advancements that impact our daily lives, from making our cities smarter to improving disease diagnosis.

She’s Got It

A growing FemTech market in Asia is empowering women to manage their reproductive health.

What’s Next In Supercomputing

Key supercomputing leaders discuss prospects, progress and possibilities in Asia-Pacific and beyond.

The Promise Of CAR T-cell Therapy In The Fight Against Cancer

CAR T-cell therapy is becoming an effective alternative for treating diffuse large B-cell lymphoma—offering better outcomes for patients with relapsed or refractory disease.